The Cellca CHO Expression Platform is a versatile, robust and scalable cell line and fed-batch process development platform. It is designed to reduce cost of goods, development risks and ultimately reduce development time. The unique platform consistently delivers robust, stable, high-yielding CHO cell lines and production processes for large and small biotech/pharma companies.
DHFR selection system and freedom to operate for all vector elements make the vector suitable for both monomeric and dimeric products.
Well characterized CHO DG44 suspension parental cell line with full cell line history. The cell line has been metabolically optimized through adaptation into chemically defined, serum-free cell culture media.
100 % chemically defined, optimized and free of animal components, proteins, and peptones. Sartorius Stedim Cellca is creator and owner of the media composition.
Simple, robust, scalable, fed-batch process for every bioreactor size and type.
From DNA to high-titre RCB in 4 months. Save up to 3 months by omitting the need for scalability studies.
More than 40 successfully completed projects using the Cellca CHO Expression Platform.
95 % of our developed cell lines deliver protein titres exceeding 3 g/L in a 12-14 day standard fed-batch process.
Processes can be easily transferred and scaled-up to a range of bioreactors up to 1000L.
Committed project teams and dedicated client manager’s make it their purpose to deliver service excellence and meet our clients requirements.
Contact our cell line development experts to discuss our unique and reliable cell line and process development platform.